New study checks if popular hair loss drug works outside of clinical trials
NCT ID NCT07226531
First seen Nov 10, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study reviews medical records of about 300 people in the US with severe alopecia areata (an autoimmune disease causing hair loss) who started taking the drug ritlecitinib. Researchers want to see how effective the drug is in real-world settings, not just in controlled trials. The goal is to understand patient characteristics, treatment patterns, and actual hair regrowth outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.